MedTrace Logo

BTA vs Baclofen for Pelvic Myofascial Pain Syndrome

NCT05617118 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2023-04-11

No results posted yet for this study

Summary

The aim of the study is to test the hypothesis that oral taking of baclofen in therapeutic dosage for 60 days is equally effective as injection of botulinum toxin type "A" in the area of trigger points of the pelvic muscles.

Conditions

  • Chronic Pain
  • Chronic Pelvic Pain Syndrome
  • Myofascial Pain Syndrome
  • Myofascial Trigger Point Pain
  • Pelvic Floor Disorders

Interventions

DRUG

Baclofen 10mg

Baclofen is a medication, a central myorelaxant, a GABAb stimulator.

DRUG

Botulinum toxin type A

Botulinum toxin, often shortened to BoNT, is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species.

Sponsors & Collaborators

  • Ural State Medical University

    collaborator OTHER

  • Saint Petersburg State University, Russia

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-12-31
Completion
2024-05-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05617118 on ClinicalTrials.gov